A review of hereditary angioedema and recombinant human C1-inhibitor treatment

European Respiratory Disease

Volumn 7, Issue 1, 2011, Pages 32-35

  Bork, Konrad ^a   Triggiani, Massimo ^b   Caballero, Teresa ^c   Relan, Anurag ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Pharming Group NV   (Netherlands)

Author keywords

C1 inhibitor; Conestat alfa; Hereditary angioedema; Recombinant protein; rhC1INH; Ruconest

Indexed keywords

EID: 84859043749     PISSN: 17545552     EISSN: 17545560     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Bork K, Meng G, Staubach P, Hardt J, Hereditary angioedema: new findings concerning symptoms, affected organs, and course, Am J Med, 2006;119(3):267-74
2. Cicardi M, Zanichelli A, Angioedema due to C1 inhibitor deficiency in 2010, Intern Emerg Med, 2010;5(6):481-6
3. Cicardi M, Agostoni A, Hereditary angioedema, N Engl J Med, 1996;334(25):1666-7
4. Roche O, Blanch A, Caballero T, et al., Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain, Ann Allergy Asthma Immunol, 2005;94(4):498-503.
5. Zuraw BL, Clinical practice. Hereditary angioedema, N Engl J Med, 2008;359(10):1027-36.
6. Prematta MJ, Kemp JG, Gibbs JG, et al., Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks, Allergy Asthma Proc, 2009;30(5):506-11.
7. Kusuma A, Relan A, Haase G, et al., Clinical value for the treatment with rhC1-INH of patients with hereditary angioedema (HAE) suffering from an acute peripheral angioedema attack, Allergy, 2010;65(s92):1182.
8. Longhurst H, Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia, Curr Opin Investig Drugs, 2008;9(3):310-23
9. Cugno M, Zanichelli A, Foieni F, et al., C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress, Trends Mol Med, 2009;15(2):69-78.
10. Kaplan AP, Ghebrehiwet B, The plasma bradykinin-forming pathways and its interrelationships with complement, Mol Immunol, 2010;47(13):2161-9
11. Bowen T, Cicardi M, Farkas H, et al., 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema, Allergy Asthma Clin Immunol, 2010;6(1):24.
12. Prematta M, Gibbs JG, Pratt EL, et al., Fresh frozen plasma for the treatment of hereditary angioedema, Ann Allergy Asthma Immunol, 2007;98(4):383-8.
13. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians, Arch Intern Med, 2001;161(20):2417-29.
14. FDA. Approval Letter - Berinert. 2009. Available at: www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/A pprovedProducts/LicensedProductsBLAs/FractionatedPlasma.Products/ucm186265.htm (accessed January 2011).
15. Craig TJ, Levy RJ, Wasserman RL, et al., Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks, J Allergy Clin Immunol, 2009;124(4):801-8.
16. Longhurst HJ, Management of acute attacks of hereditary angioedema: potential role of icatibant, Vasc Health Risk Manag, 2010;6:795-802
17. Stolz LE, Horn PT, Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema, Drugs Today (Barc), 2010;46(8):547-55
18. Longhurst HJ, Carr S, Khair K, C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option, Clin Exp Immunol, 2007;147(1):11-7
19. Longhurst HJ, Farkas H, Craig T, et al., HAE international home therapy consensus document, Allergy Asthma Clin Immunol, 2010;6(1):22.
20. Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, et al., C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis, Transfusion, 2009;49(9):1987-95.
21. Zuraw BL, Busse PJ, White M, et al., Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema, N Engl J Med, 2010;363(6):513-22.
22. FDA. Approval Letter - Cinryze. 2008. Available at: www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/A pprovedProducts/LicensedProductsBLAs/FractionatedPlasma.Products/ucm093602.htm (accessed January 2011).
23. van Doorn MB, Burggraaf J, van Dam T, et al., A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema, J Allergy Clin Immunol, 2005;116(4):876-83.
24. Cugno M, Nuijens J, Hack E, et al. Plasma levels of C1-inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema, J Clin Invest, 1990;85(4):1215-20.
25. Ruconest Summary of Product Characteristics, 2010. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001223/WC500098542.pdf (accessed December 2010).
26. Choi G, Soeters MR, Farkas H, et al., Recombinant human C1-inhibitor in the treatment of acute angioedema attacks, Transfusion, 2007;47(6):1028-32.
27. Zuraw B, Cicardi M, Levy RJ, et al., Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema, J Allergy Clin Immunol, 2010;126(4):821-7 e14.
28. ® C1 Esterase Inhibitor (Human) US Package Insert. Revised: November 2009. Available at: www.berinert.com/docs/Berinert_pi.pdf (accessed December 2010).